Results 131 to 140 of about 50,061 (215)

What Is Your Diagnosis? Lymph Node Aspirate From a Dog

open access: yes
Veterinary Clinical Pathology, EarlyView.
William Benedict   +3 more
wiley   +1 more source

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

open access: yesMolecular Oncology, Volume 20, Issue 11, Page 2784-2804, November 2026.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas   +16 more
wiley   +1 more source

Contralateral Cutaneous T-cell Lymphoma as a Mimicker of Multi-decade Atopic Dermatitis. [PDF]

open access: yesCureus
Dasher A   +6 more
europepmc   +1 more source

Utilization of immune checkpoint inhibitors for the treatment of cancer in Scotland, 2018–2024: A national retrospective cohort study

open access: yesBritish Journal of Clinical Pharmacology, Volume 92, Issue 11, Page 3972-3981, November 2026.
Aims The aim of the study is to describe the use of immune checkpoint inhibitors (ICIs) for the treatment of cancer in Scotland. Methods The retrospective observational cohort study included patients aged 18 years or older who commenced treatment with an ICI in Scotland between 1 January 2018 and 31 December 2024.
Tanja Mueller   +9 more
wiley   +1 more source

High Level of Component C1q Binding Protein (C1QBP) is Associated With Poor Prognosis and Dysfunction of Mast Cells in Lung Adenocarcinoma

open access: yesCancer Medicine, Volume 15, Issue 11, November 2026.
ABSTRACT Background Component C1q binding protein (C1QBP) is known as an important regulator of mitochondrial plasticity and is involved in antitumor immune response in cancers. Nevertheless, its role in lung adenocarcinoma (LUAD) still remains largely unknown.
Wei Li   +9 more
wiley   +1 more source

Empirical PK/PD Model for Differentiating Intrinsic Dosing Rules by Therapeutic Indication With Relevance for HIV‐1 Latency Reversal

open access: yesClinical Pharmacology &Therapeutics, Volume 120, Issue 5, Page 1414-1426, November 2026.
Romidepsin (RMD), an FDA‐approved histone deacetylase inhibitor for treating cancer, demonstrates potent latency‐reversing activity in vitro but has yielded suboptimal outcomes in kick‐and‐kill HIV‐cure trials when administered as a 5 mg/m2 infusion.
Lauren A. R. Tompkins   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy